Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resiquimod Gel for Common Warts
NCT00114920Phase 2Completed
- Sponsor
- Graceway Pharmaceuticals
- Start
- Mar 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-blind trial of resiquimod in common warts (4 arms), sponsored by Graceway Pharmaceuticals. Primary endpoint: Clearance of treated common wart(s) at 12 weeks. Started Mar 2004; status: completed.
02
Drugs
resiquimod
03
Conditions
common warts
Beyond the preview
Go deeper on NCT00114920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00114920.